The crypto-funded peptide market has surpassed an annual run rate of over $100 million after Q1 sales reached $32 million, a 159% increase sequentially, according to a new report from Chainalysis.
summary
Chainalysis says the annual run rate of the crypto-funded peptide market has exceeded $100 million. Peptide sales for the first quarter of 2026 were $32 million, an increase of 159% sequentially. The average spend on independent purity testing has fallen by 88% per purchaser, and safety concerns are growing as demand for peptides continues to grow.
According to Chainalysis, demand for off-label peptides is rapidly expanding beyond the niche biohacking community, creating a gray market industry increasingly reliant on cryptocurrency payments.
According to the blockchain analytics firm, peptide purchases reached $32 million in the first quarter of 2026, up from $12 million in the previous quarter.
Peptides, short chains of amino acids used in health, fitness and wellness products, are gaining attention following the success of GLP-1 drugs such as Ozempic and Wegovy. Chainalysis said growing consumer interest in weight loss, performance enhancement and recovery products has led to buyers flocking to alternative peptide suppliers operating outside of traditional pharmaceutical channels.
Many of these suppliers are based in China, and access to traditional banking services may be limited for companies selling prescription-grade compounds or unregulated substances. As a result, cryptocurrencies have become an important payment method connecting manufacturers and overseas buyers, Chainalysis said.
Stablecoins are becoming the preferred payment method
Chainalysis, which investigated on-chain activity related to major peptide vendors, found that large suppliers increasingly prefer stablecoins over more volatile cryptocurrencies.
The company said vendors receiving an average deposit amount of at least $1,000 exhibit a stablecoin-dominated payment mix, suggesting an effort to reduce exposure to cryptocurrency price fluctuations while processing large-scale supply chain transactions.
Chainalysis says what started as a small marketplace for professional buyers has evolved into a more organized ecosystem.
The report noted that major vendors are adopting increasingly sophisticated on-chain financial practices while continuing to process large volumes of transactions through Bitcoin and stablecoins.
Chainalysis compared peptide trading to other gray market industries that have historically turned to cryptocurrencies due to restrictions from banks and payment processors. The company said its suppliers can offer raw, unbranded products directly to consumers at prices far lower than those available through regulated channels.
This finding also applies to broader trends previously identified by Chaina Analysis. Earlier this year, the company reported that the stablecoin-centered network operates through Telegram and other online platforms, and that the flow of cryptocurrencies to suspected human trafficking services increased by 85% in 2025.
Chainalysis said blockchain’s transparency nevertheless provides investigators with a permanent record of transactions that can help track financial activity and identify key intermediaries.
Spending on quality testing declines despite increased demand
In addition to increased sales, Chainalysis identified a decline in peptide buyers’ spending on independent product testing.
The company said many customers previously sent money to both the peptide supplier and Janosik, a Czech-based laboratory that tests chemical purity. However, as the number of buyers increased rapidly, testing costs could no longer keep up with sales growth.
Chainaosis estimates that even though Janoshik is conducting more tests than before, average testing spend per buyer has decreased by 88% to about $8. This decline occurred as new demand entered the market faster than testing activity expanded.
Safety concerns have also been raised regarding some suppliers participating in the industry. Chainalysis reports that Shanghai Sigma Audrey has links to organizations previously involved in selling fentanyl precursors and generated at least $1 million in Bitcoin and $3.59 million in stablecoins before expanding into peptide sales.
Given the combination of unregulated products and crypto-based transactions, Chainalysis warned that many new customers entering the space may have limited experience in either market, increasing potential risks as the industry continues to grow.
